clinical trial · NCT07642050
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
Biohaven Therapeutics Ltd.·phase3·not yet recruiting·n = 420
IgA NephropathyBHV-1400Placebo
brief summary
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
started
Jun 1, 2026
primary completion
Sep 1, 2028
completion
Oct 1, 2029
last updated
Jun 11, 2026
official title
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BHV-1400 in the Treatment of IgA Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol